Danapha (DAN): niche domestic pharma with modest upside but concentrated ownership and low liquidity
Intrinsic value VND 36,802 vs market VND 32,900 — implied upside 11.9% (confidence: low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược Danapha is a UPCoM-listed domestic pharmaceutical company operating in the 'Dược phẩm' segment. The company generates biannual-scale revenues (VND 647.3 bn in 2025) and sells finished pharmaceutical products and related consumer-health items to the domestic market. Danapha is small-cap and thinly traded (avg volume 2w: 157 shares), and the exchange listing on UPCoM contributes to lower liquidity and visibility relative to HoSE/HNX peers.
Ownership is highly concentrated: Công ty TNHH Danhson VN holds 70.97% and Tổng Công ty Dược Việt Nam holds 26.45% of shares, leaving limited free float and restricted governance dynamics. The share register structure and limited free float (foreign_room: 10449653.07862) materially constrain market liquidity and the stock's responsiveness to fundamentals and catalyst events.
Luận điểm đầu tư
Danapha combines a defendable margin profile with modest growth: gross profit margin stood at 55.0% and EBIT margin 21.7% in the latest reported metrics, while net profit recovered to VND 85.7 bn in 2025 from VND 70.0 bn in 2024. The company reports ROE of 10.6% and a P/E of 8.0x, implying the market already prices the company as a value-style, domestically oriented pharma.
Valuation from our blended model places intrinsic value at VND 36,802 per share (11.9% upside vs the VND 32,900 market price). The valuation is driven primarily by a DCF component (70% weight) using a WACC of 10.0% and terminal growth of 4.0% across a 10-year projection. However, the model's confidence is low (recalibrated), and the raw model outcome was adjusted (raw_intrinsic_value VND 44,320.4) through an isotonic calibration — indicating material model uncertainty.
Key negatives that temper conviction: extremely concentrated ownership (combined ~97.4% by two institutions) limits float and can entrench strategic decisions; liquidity is poor (avg 2w volume 157) and UPCoM listing reduces investor access; leverage is elevated with Debt/Equity 1.56 which increases sensitivity to revenue shocks. Earnings quality is middling (61.7/100), and there are no explicit forensic M-Score flags but limited public disclosure depth and the illiquid sanity_flag warrant caution.
Taken together, the implied upside (11.9%) is too narrow given execution, liquidity and governance risks, and the model's low confidence. The investment case is therefore one of selective exposure for yield/valuation-minded investors willing to accept governance and liquidity constraints rather than a high-conviction growth buy.
Diễn giải định giá
Blended intrinsic valuation: 70% DCF (10-year projection, terminal value) and 30% PE-based cap, producing a calibrated intrinsic value.
- Base free cash flow input: base_fcf VND 80,715,382,317 (model input).
- Discount rate / WACC = 10.0%; terminal growth = 4.0%; projection years = 10.
- Blend weights: DCF 70%, PE 30%; fair PE used in PE leg = 10.95x with PE cap 25x.
- TV (terminal value) accounts for 57.5% of enterprise value in the DCF (tv_pct 0.575).
- Model calibration produced raw_intrinsic_value VND 44,320.4 before isotonic calibration to reported intrinsic VND 36,802.
The model implies 11.9% upside vs the current price but has low confidence. The DCF dominates valuation (70% weight) and is sensitive to a 10.0% WACC and 4.0% terminal growth — small changes materially move the intrinsic value. Given concentrated ownership, low liquidity and model recalibration, our confidence in the precision of the intrinsic estimate is limited.
Các luận điểm cần cân nhắc
- Attractive current multiples: P/E 8.0x and P/B 0.81 signal valuation support relative to growth prospects.
- Strong margin profile: gross profit margin 55.0% and EBIT margin 21.7% underpin free-cash-generation potential.
- Recent revenue and profit recovery: revenue rose to VND 647.3 bn in 2025 and net profit recovered to VND 85.7 bn, supporting the model's base FCF assumptions.
- Extremely concentrated ownership (70.97% + 26.45%) leaves free float tiny and governance / liquidity risks high.
- Illiquidity and UPCoM listing: avg volume 2w of 157 shares and 'illiquid' sanity_flag increase execution risk for institutional flows.
- Leverage and balance-sheet expansion: Debt/Equity 1.56 increases financial risk if margins or volumes soften.
- Model confidence is low and the intrinsic estimate was recalibrated (isotonic), indicating material valuation uncertainty.
Bối cảnh ngành
Danapha sits in the Vietnamese pharmaceutical (Dược phẩm) sub-sector where domestic producers compete on cost, distribution relationships and product registration pipelines. Sector dynamics include regulatory oversight on pricing and registration, and differing recognition rules under VAS vs IFRS that can affect reported profits and capex timing. For state-influenced peers, SOE mandates (dividend or strategic objectives) and relationships with Tổng Công ty Dược Việt Nam can be material — here, that SOE holds 26.45% is a relevant governance factor.
Peer valuation dispersion is notable: the sector median upside is 12.1% (351 peers), roughly in line with Danapha’s 11.9% implied upside. Top peer examples show upside >36% for some names, but those often come with higher confidence. In Vietnam, banks and larger industrials also carry state-related distortions (VAMC bonds, SBV quotas) which are less directly relevant to Danapha, but the broader market's liquidity and foreign participation environment affects small-cap pharmas disproportionately.
Yếu tố rủi ro
- Very concentrated ownership (~97.4% held by two institutions) limits free-float and increases the risk that minority shareholders have low influence on strategy and distributions.
- Low trading liquidity (avg volume 2w: 157) and UPCoM listing make market exits and price discovery unreliable for large orders.
- Leverage: Debt/Equity of 1.56 raises financial risk if revenue or margins deteriorate.
- Model and valuation uncertainty: valuation confidence is low and model required isotonic calibration (raw_intrinsic_value VND 44,320.4 to calibrated VND 36,802).
- Earnings quality only moderate (61.7/100), implying some caution on sustainability of profit margins and cash flow conversion.
- Regulatory and product-registration risk in pharma can delay launches and compress margins; state ownership may also influence procurement channels and pricing.
Yếu tố có thể tác động
- Better-than-expected 2026 results (revenue and net profit above model assumptions) could validate the DCF base and lift the calibrated intrinsic value.
- Increased liquidity or a move to a main exchange (HoSE/HNX) or a shareholder restructuring that increases free float would materially reduce the liquidity discount.
- Operational improvements that expand EBIT margin or ROE above current 10.6% could justify a higher fair PE and boost intrinsic value.
Đánh giá dấu hiệu kế toán
There are no M-Score or explicit forensic red flags in the input (mscore: null, no red_flags). That said, earnings quality is moderate at 61.7/100 — not an outright alarm but not a pristine signal either. The more salient forensic concerns are structural: very high ownership concentration and UPCoM listing reduce transparency and minority governance protections relative to larger exchange-listed peers. Absent M-Score flags, focus should be on cash-flow conversion and related-party transactions disclosed in filings.
Lịch sử định giá
Model track record over six years shows a hit rate of 40% (0.4), meaning the model's directional calls (defined as >10% upside) matched subsequent price movement in 40% of years — a modest historical performance. The model's average realized upside in those years was 41.5%, but given the low hit rate and the small-cap, illiquid nature of the stock, past performance should be treated cautiously as a guide rather than a reliable predictor.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.